PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
2470856-5	1989	Long SP C-terminal fragments were more potent than shorter ones in stimulating the accumulation of 3H-inositol phosphates.	3h-inositol phosphates	99-121	sparse coat	Mus musculus	5-9
35121255-8	2022	Immunofluorescence assays showed decreased levels of SP-C and increased levels of KL-6 in the PS-MPs group.	ps-mps	94-100	sparse coat	Mus musculus	53-57
35111059-12	2021	Posttreatment with aspirin also reduced hyperoxia-induced increases in the numbers of lung macrophages, intracellular ROS levels, and the expression of TNF-alpha, IL-1beta, and IL-4; it also increased CC10, SPC and Nrp-1 levels compared with hyperoxia exposure alone.	Aspirin	19-26	sparse coat	Mus musculus	207-210
35183536-9	2022	A prolonged pre-exposure to capsaicin or BIBN4096 (1 muM), a CGRP receptor antagonist, inhibited the mechanostimulation-induced reduction in the SPC frequency, but did not block the increase in SPC amplitude.	Capsaicin	28-37	sparse coat	Mus musculus	145-148
35183536-9	2022	A prolonged pre-exposure to capsaicin or BIBN4096 (1 muM), a CGRP receptor antagonist, inhibited the mechanostimulation-induced reduction in the SPC frequency, but did not block the increase in SPC amplitude.	1-(N(2)-(3,4-dibromo-N-((4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl)carbonyl)tyrosyl)lysyl)-4-(4-pyridinyl)piperazine	41-49	sparse coat	Mus musculus	145-148
2428383-6	1986	SP-C decreased both nigral 5-hydroxyindoleacetic acid/5-hydroxytryptamine (5-HIAA/5-HT) and, to a lesser extent, 3,4-dihydroxyphenylacetic acid/dopamine, while SP-N increased nigral 5-HIAA/5-HT.	nigral 5-hydroxyindoleacetic acid	20-53	sparse coat	Mus musculus	0-4
2428383-6	1986	SP-C decreased both nigral 5-hydroxyindoleacetic acid/5-hydroxytryptamine (5-HIAA/5-HT) and, to a lesser extent, 3,4-dihydroxyphenylacetic acid/dopamine, while SP-N increased nigral 5-HIAA/5-HT.	Serotonin	54-73	sparse coat	Mus musculus	0-4
2428383-6	1986	SP-C decreased both nigral 5-hydroxyindoleacetic acid/5-hydroxytryptamine (5-HIAA/5-HT) and, to a lesser extent, 3,4-dihydroxyphenylacetic acid/dopamine, while SP-N increased nigral 5-HIAA/5-HT.	Hydroxyindoleacetic Acid	75-81	sparse coat	Mus musculus	0-4
2428383-6	1986	SP-C decreased both nigral 5-hydroxyindoleacetic acid/5-hydroxytryptamine (5-HIAA/5-HT) and, to a lesser extent, 3,4-dihydroxyphenylacetic acid/dopamine, while SP-N increased nigral 5-HIAA/5-HT.	3,4-Dihydroxyphenylacetic Acid	113-143	sparse coat	Mus musculus	0-4
2428383-6	1986	SP-C decreased both nigral 5-hydroxyindoleacetic acid/5-hydroxytryptamine (5-HIAA/5-HT) and, to a lesser extent, 3,4-dihydroxyphenylacetic acid/dopamine, while SP-N increased nigral 5-HIAA/5-HT.	Dopamine	144-152	sparse coat	Mus musculus	0-4
2428383-6	1986	SP-C decreased both nigral 5-hydroxyindoleacetic acid/5-hydroxytryptamine (5-HIAA/5-HT) and, to a lesser extent, 3,4-dihydroxyphenylacetic acid/dopamine, while SP-N increased nigral 5-HIAA/5-HT.	Hydroxyindoleacetic Acid	76-81	sparse coat	Mus musculus	0-4
6177781-6	1982	Irrespective of whether donors received BP in IFA or CFA, BP-cultured spleen and lymph node cells (SpC and LNC, respectively) transferred EAE, whereas Con A-cultured SpC but not LNC exhibited effector cell activity.	Benzo(a)pyrene	58-60	sparse coat	Mus musculus	99-102
33923773-6	2021	The results showed that both GPL and SPC exerted excellent synergistic effect with CUR in inhibiting the lipopolysaccharide (LPS)-induced secretion of nitric oxide (NO), reactive oxygen species (ROS), and pro-inflammatory genes (tumor necrosis factor (TNF)-alpha, interleukin 1beta (IL-beta), and interleukin 6 (IL-6)) in RAW264.7 cells.	Curcumin	83-86	sparse coat	Mus musculus	37-40
1087353-5	1976	The suppressive effect could still be demonstrated by addition of SpC from TB mice 24 or 48 hours after phytohemagglutinin stimulation of normal SpC, SpC from TB C3H/He mice inhibited mitogen-induced stimulation of both C3H/He and DBA/2 lymphocytes.	Helium	166-168	sparse coat	Mus musculus	66-69
33923773-6	2021	The results showed that both GPL and SPC exerted excellent synergistic effect with CUR in inhibiting the lipopolysaccharide (LPS)-induced secretion of nitric oxide (NO), reactive oxygen species (ROS), and pro-inflammatory genes (tumor necrosis factor (TNF)-alpha, interleukin 1beta (IL-beta), and interleukin 6 (IL-6)) in RAW264.7 cells.	Reactive Oxygen Species	170-193	sparse coat	Mus musculus	37-40
33923773-6	2021	The results showed that both GPL and SPC exerted excellent synergistic effect with CUR in inhibiting the lipopolysaccharide (LPS)-induced secretion of nitric oxide (NO), reactive oxygen species (ROS), and pro-inflammatory genes (tumor necrosis factor (TNF)-alpha, interleukin 1beta (IL-beta), and interleukin 6 (IL-6)) in RAW264.7 cells.	Nitric Oxide	151-163	sparse coat	Mus musculus	37-40
33923773-6	2021	The results showed that both GPL and SPC exerted excellent synergistic effect with CUR in inhibiting the lipopolysaccharide (LPS)-induced secretion of nitric oxide (NO), reactive oxygen species (ROS), and pro-inflammatory genes (tumor necrosis factor (TNF)-alpha, interleukin 1beta (IL-beta), and interleukin 6 (IL-6)) in RAW264.7 cells.	Reactive Oxygen Species	195-198	sparse coat	Mus musculus	37-40
31144406-3	2019	Here, we have found that carcinogen nicotine-derived nitrosaminoketone (NNK)-induced tumors developing in Tg-SPC-SFN+/- mice show a similar histology to human lung adenocarcinoma and exhibit high hSFN expression.	Nicotine	36-44	sparse coat	Mus musculus	109-112
31860803-5	2020	To test this, we generated mice with tamoxifen-inducible deletion of FGF receptors 1, 2 and 3 in SPC+ AEC2s (SPC-TCKO).	Tamoxifen	37-46	sparse coat	Mus musculus	97-100
31860803-5	2020	To test this, we generated mice with tamoxifen-inducible deletion of FGF receptors 1, 2 and 3 in SPC+ AEC2s (SPC-TCKO).	Tamoxifen	37-46	sparse coat	Mus musculus	109-112
31860803-7	2020	After intratracheal bleomycin administration, SPC-TCKO mice had increased mortality, lung edema, and BAL total protein, and flow cytometry and immunofluorescence revealed a loss of AEC2s.	Bleomycin	20-29	sparse coat	Mus musculus	46-49
31860803-8	2020	To reduce mortality of SPC-TCKO mice to <50%, a 25-fold dose reduction of bleomycin was required.	Bleomycin	77-86	sparse coat	Mus musculus	23-26
31860803-9	2020	Surviving bleomycin-injured SPC-TCKO mice had increased collagen deposition, fibrosis, alphaSMA expression, and decreased epithelial gene expression.	Bleomycin	10-19	sparse coat	Mus musculus	28-31
31907045-5	2020	DSF/SPC-NSps, having a spherical appearance with particle size of 155 nm, could remain very stable in different physiological media, and sustained release.	Disulfiram	0-3	sparse coat	Mus musculus	4-7
31907045-6	2020	The in vitro MTT assay indicated that the cytotoxicity of DSF/SPC-NSps was enhanced remarkably compared to free DSF against the 4T1 cell line.	thiazolyl blue	13-16	sparse coat	Mus musculus	62-65
31907045-6	2020	The in vitro MTT assay indicated that the cytotoxicity of DSF/SPC-NSps was enhanced remarkably compared to free DSF against the 4T1 cell line.	Disulfiram	58-61	sparse coat	Mus musculus	62-65
31907045-6	2020	The in vitro MTT assay indicated that the cytotoxicity of DSF/SPC-NSps was enhanced remarkably compared to free DSF against the 4T1 cell line.	Disulfiram	112-115	sparse coat	Mus musculus	62-65
31907045-8	2020	DSF/SPC-NSps groups administered via intravenous injections exhibited better antitumor efficacy compared to the commercial paclitaxel injection (PTX injection) and had a dose-dependent effect in vivo.	Paclitaxel	123-133	sparse coat	Mus musculus	4-7
31907045-8	2020	DSF/SPC-NSps groups administered via intravenous injections exhibited better antitumor efficacy compared to the commercial paclitaxel injection (PTX injection) and had a dose-dependent effect in vivo.	pectenotoxin 1	145-148	sparse coat	Mus musculus	4-7
31144406-3	2019	Here, we have found that carcinogen nicotine-derived nitrosaminoketone (NNK)-induced tumors developing in Tg-SPC-SFN+/- mice show a similar histology to human lung adenocarcinoma and exhibit high hSFN expression.	nitrosaminoketone	53-70	sparse coat	Mus musculus	109-112
31144406-3	2019	Here, we have found that carcinogen nicotine-derived nitrosaminoketone (NNK)-induced tumors developing in Tg-SPC-SFN+/- mice show a similar histology to human lung adenocarcinoma and exhibit high hSFN expression.	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	72-75	sparse coat	Mus musculus	109-112
30010471-7	2018	Antioxidant vitamin C restored the LPS induced down-regulation of ABCA3, SP-C and GATA-6 in MLE-12 cells.	Ascorbic Acid	12-21	sparse coat	Mus musculus	73-77
29082763-8	2019	Expression of Cldn18 and surfactants (SPA, SPB and SPC) were significantly induced in MLE12 after DCI treatment.	dci	98-101	sparse coat	Mus musculus	51-54
29082763-9	2019	Silencing of Cldn18 effectively suppressed the DCI-induced expression of SPB and SPC but not SPA.	dci	47-50	sparse coat	Mus musculus	81-84
30010471-8	2018	Furthermore, LPS induced activation of NF-kappaB signaling in MLE-12 cells, and the LPS-induced decrease in SP-C expression was partially abrogated by blocking NF-kappaB signaling with Bay-11-7082.	bay-11	185-191	sparse coat	Mus musculus	108-112
28287822-7	2017	Upon dox treatment of adults, deletion in ATII cells and integrin beta4+ cells in SP-C-tTg mice dropped significantly to ~20% and ~6%, respectively, whereas CCSP-tTg mice deleted in ~57% of ATII and ~40% of integrin beta4+ cells.	Doxycycline	5-8	sparse coat	Mus musculus	82-86
28552795-9	2017	Moreover, positive DAB staining of PCNA, SP-B & SP-C was observed due to rHuKGF supplementation at tissue level.	diazobenzenesulfonic acid	19-22	sparse coat	Mus musculus	52-56
28287822-5	2017	With dox exposure during lung development, SP-C-tTg mice deleted in ~65-75% of alveolar epithelial type II (ATII) cells, but in only ~45-50% of the integrin beta4+ population, which consisted of club cells and distal lung progenitor cells.	Doxycycline	5-8	sparse coat	Mus musculus	43-47
26936095-6	2016	The effects of miRNA-196a on the sensitivity of SPC-A-1 cells to cisplatin in vivo were determined using BALB/c nude mice.	Cisplatin	65-74	sparse coat	Mus musculus	48-51
27286338-6	2017	The flow cytometry analysis indicated curzerene arrested the cells in the G2/M cell cycle and promoted or induced apoptosis of SPC-A1 cells.	curzerene	38-47	sparse coat	Mus musculus	127-130
27286338-8	2017	Western blot and RT-PCR analysis demonstrated that curzerene induced the downregulation of GSTA1 protein and mRNA expressions in SPC-A1 cells.	curzerene	51-60	sparse coat	Mus musculus	129-132
27286338-9	2017	Tumor growth was significantly inhibited in SPC-A1 cell-bearing nude mice by using curzerene (135 mg/kg daily), meanwhile, curzerene did not significantly affect body mass and the organs of the mice, which may indicate that curzerene has limited toxicity and side effects in vivo.	curzerene	83-92	sparse coat	Mus musculus	44-47
27286338-11	2017	Focusing on its relationship with GSTA1, curzerene could induce the downregulation of GSTA1 protein and mRNA expressions in SPC-A1 cells.	curzerene	41-50	sparse coat	Mus musculus	124-127
25517107-6	2015	RESULTS: SPC-RelA mice showed significant increases in lung inflammation and injury following LPS injection with increased neutrophil recruitment as compared to wild type and saline treated controls.	Sodium Chloride	175-181	sparse coat	Mus musculus	9-12
26066828-9	2015	Furthermore, DeltaH showed a strong negative correlation with both SP-B (r(2) = 0.801) and SP-C (r(2) = 0.810) content.	deltah	13-19	sparse coat	Mus musculus	91-95
25316003-5	2015	While KGF synergistically supports the inducing effect of DCI on alveolar markers with increased expression of surfactant protein (SP)-C and SP-B, an inhibitory effect on CCSP expression was shown.	dci	58-61	sparse coat	Mus musculus	111-136
23176317-8	2013	Again, KGF and DCI synergistically increased SP-C and SP-B expression in iPSC cultures, and lacZ expressing ATII-like cells developed.	dci	15-18	sparse coat	Mus musculus	45-49
23154940-4	2013	The levels of surfactant protein (SP) C, SPB, and SPD, the specific markers of AT II cells, correspondingly increased in mMSCs when Wnt3a or LiCl was added to the co-culture system to activate wnt/beta-catenin signaling.	Lithium Chloride	141-145	sparse coat	Mus musculus	14-39
23385154-3	2013	SPC-54 blocked active site titration of purified APC using the active site titrant, biotinylated FPR-chloromethylketone, showing that SPC-54 blocks access to APC"s active site to inhibit all enzymatic activity.	chloromethylketone	101-119	sparse coat	Mus musculus	0-3
23385154-3	2013	SPC-54 blocked active site titration of purified APC using the active site titrant, biotinylated FPR-chloromethylketone, showing that SPC-54 blocks access to APC"s active site to inhibit all enzymatic activity.	chloromethylketone	101-119	sparse coat	Mus musculus	134-137
23385154-4	2013	A single injection of SPC-54 (10mg/kg) neutralized circulating PC in mice for at least 7days, and immunoblotting and immuno-precipitation with protein G-agarose confirmed that SPC-54 in vivo was bound to PC in plasma.	Sepharose	153-160	sparse coat	Mus musculus	176-179
23385154-6	2013	SPC-54 decreased lung perfusion in this model by 54% when monitored by vascular perfusion methodologies using infrared fluorescence of Evans blue dye.	Evans Blue	135-149	sparse coat	Mus musculus	0-3
21169555-4	2011	Overexpression of the surfactant protein (SP)-C BRICHOS mutant SP-C(DeltaExon4) in A549 cells increased Grp78 and alpha-SMA and disrupted ZO-1 distribution, and, in primary AECs, SP-C(DeltaExon4) induced fibroblastic-like morphology, decreased ZO-1 and E-cadherin and increased alpha-SMA, mechanistically linking ER stress associated with mutant SP to fibrosis through EMT.	sp	42-44	sparse coat	Mus musculus	63-67
22643035-16	2012	BrdU+CD45+ cells increased by 0.7-fold and SPC+CC10+ bronchoalveolar stem cells (BASC), decreased by ~40-fold post-bleomycin.	Bleomycin	115-124	sparse coat	Mus musculus	43-46
21169555-4	2011	Overexpression of the surfactant protein (SP)-C BRICHOS mutant SP-C(DeltaExon4) in A549 cells increased Grp78 and alpha-SMA and disrupted ZO-1 distribution, and, in primary AECs, SP-C(DeltaExon4) induced fibroblastic-like morphology, decreased ZO-1 and E-cadherin and increased alpha-SMA, mechanistically linking ER stress associated with mutant SP to fibrosis through EMT.	sp	42-44	sparse coat	Mus musculus	179-183
19013447-0	2009	rtTA toxicity limits the usefulness of the SP-C-rtTA transgenic mouse.	rtta	0-4	sparse coat	Mus musculus	43-47
20360252-12	2010	LPA20:4-induced SPC mobilization and neointima formation were blocked by Ki16425, LPA(1)- and LPA(3)-specific small interfering (si)RNA, and the CXCR4 antagonist POL5551.	3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid	73-80	sparse coat	Mus musculus	16-19
20360252-13	2010	Ki16425 reduced LPA20:4-mediated neointimal recruitment of SPC as demonstrated by 2-photon microscopy in bone marrow chimeric mice after repopulation with SM22-LacZ transgenic, hematopoietic cells.	3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid	0-7	sparse coat	Mus musculus	59-62
19117480-6	2009	We successfully applied F-SERS dots for the detection of three cellular proteins, including CD34, Sca-1, and SP-C.	Serine	26-30	sparse coat	Mus musculus	109-113
19013447-3	2009	Here we report that DOX-fed SP-C-rtTA mice during the period in which Type II cells differentiate results in cellular toxicity that may have confounded the interpretation of previous reports using this line.	Doxycycline	20-23	sparse coat	Mus musculus	28-32
19013447-6	2009	However, quantitative analysis reveled that DOX-fed, SP-C-rtTA C57BL/6 pups had reduced surfactant mRNA accumulation that could contribute to synthetic lethality when combined with other genetic alterations.	Doxycycline	44-47	sparse coat	Mus musculus	53-57
18330476-6	2008	Tumor growth inhibition was observed in SPC-A1 xenograft-bearing mice that received eight intratumoral injections of GA5-polyethylenimine/p53 complexes in 3 weeks.	ga5-polyethylenimine	117-137	sparse coat	Mus musculus	40-43
18710947-7	2008	SPC recruitment and protein changes were inhibited by siRNA specific to lactate dehydrogenase, TrxR, or HIF-1 and by oxamate, apocynin, U0126, N-acetylcysteine, dithioerythritol, and antibodies to VEGF or SDF-1.	Oxamic Acid	117-124	sparse coat	Mus musculus	0-3
18710947-7	2008	SPC recruitment and protein changes were inhibited by siRNA specific to lactate dehydrogenase, TrxR, or HIF-1 and by oxamate, apocynin, U0126, N-acetylcysteine, dithioerythritol, and antibodies to VEGF or SDF-1.	U 0126	136-141	sparse coat	Mus musculus	0-3
18710947-7	2008	SPC recruitment and protein changes were inhibited by siRNA specific to lactate dehydrogenase, TrxR, or HIF-1 and by oxamate, apocynin, U0126, N-acetylcysteine, dithioerythritol, and antibodies to VEGF or SDF-1.	Acetylcysteine	143-159	sparse coat	Mus musculus	0-3
18710947-7	2008	SPC recruitment and protein changes were inhibited by siRNA specific to lactate dehydrogenase, TrxR, or HIF-1 and by oxamate, apocynin, U0126, N-acetylcysteine, dithioerythritol, and antibodies to VEGF or SDF-1.	Dithioerythritol	161-177	sparse coat	Mus musculus	0-3
18710947-8	2008	Oxidative stress from lactate metabolism by SPCs accelerated further SPC recruitment and differentiation through Trx1-mediated elevations in HIF-1 levels and the subsequent synthesis of HIF-1-dependent growth factors.	Lactic Acid	22-29	sparse coat	Mus musculus	44-47
18523246-3	2008	In this study, we determined whether the lysophospholipids, i.e., LPC and sphingosylphosphorylcholine (SPC), modulate the ATP-induced release and processing of IL-1beta mediated by P2X7R in mouse MG6 microglial cells.	Lysophospholipids	41-58	sparse coat	Mus musculus	103-106
18523246-3	2008	In this study, we determined whether the lysophospholipids, i.e., LPC and sphingosylphosphorylcholine (SPC), modulate the ATP-induced release and processing of IL-1beta mediated by P2X7R in mouse MG6 microglial cells.	sphingosine phosphorylcholine	74-101	sparse coat	Mus musculus	103-106
18523246-3	2008	In this study, we determined whether the lysophospholipids, i.e., LPC and sphingosylphosphorylcholine (SPC), modulate the ATP-induced release and processing of IL-1beta mediated by P2X7R in mouse MG6 microglial cells.	Adenosine Triphosphate	122-125	sparse coat	Mus musculus	103-106
18523246-6	2008	Conversely, ATP inhibited the release of pro-IL-1beta and mIL-1beta induced by LPC/SPC.	Adenosine Triphosphate	12-15	sparse coat	Mus musculus	83-86
18523246-8	2008	P2X7R activation resulted in microtubule reorganization in the MG6 cells that was blocked in the presence of LPC and SPC.	mg6	63-66	sparse coat	Mus musculus	117-120
18523246-9	2008	LPC/SPC reduced the amount of activated RhoA after stimulation with ATP, implying that these lysophospholipids block ATP-induced microtubule reorganization by interfering with RhoA activation.	Adenosine Triphosphate	68-71	sparse coat	Mus musculus	4-7
18523246-9	2008	LPC/SPC reduced the amount of activated RhoA after stimulation with ATP, implying that these lysophospholipids block ATP-induced microtubule reorganization by interfering with RhoA activation.	Lysophospholipids	93-110	sparse coat	Mus musculus	4-7
18523246-9	2008	LPC/SPC reduced the amount of activated RhoA after stimulation with ATP, implying that these lysophospholipids block ATP-induced microtubule reorganization by interfering with RhoA activation.	Adenosine Triphosphate	117-120	sparse coat	Mus musculus	4-7
18523246-11	2008	This suggests that the impairment of the microtubule reassembly may be associated with the inhibitory effects of LPC/SPC on ATP-induced mIL-1beta release.	Adenosine Triphosphate	124-127	sparse coat	Mus musculus	117-120
16166744-9	2006	Meanwhile, HIMF increased transcription activity and prevented actinomycin D-facilitated SP-B and SP-C mRNA degradation in MLE-12 cells.	Dactinomycin	63-76	sparse coat	Mus musculus	98-102
16166744-10	2006	Incubation of cells with LY294002, PD098059, or U0126 abolished HIMF-induced Akt and ERK1/2 phosphorylation and suppressed HIMF-induced SP-B and SP-C production, whereas SB203580 had no effect.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	25-33	sparse coat	Mus musculus	145-149
16166744-10	2006	Incubation of cells with LY294002, PD098059, or U0126 abolished HIMF-induced Akt and ERK1/2 phosphorylation and suppressed HIMF-induced SP-B and SP-C production, whereas SB203580 had no effect.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	35-43	sparse coat	Mus musculus	145-149
16166744-10	2006	Incubation of cells with LY294002, PD098059, or U0126 abolished HIMF-induced Akt and ERK1/2 phosphorylation and suppressed HIMF-induced SP-B and SP-C production, whereas SB203580 had no effect.	U 0126	48-53	sparse coat	Mus musculus	145-149
12538780-5	2003	Dex 10(-9) to 10(-7) M increased SP-A and SP-B mRNA 1.5-fold and SP-C mRNA two-fold.	Dexamethasone	0-3	sparse coat	Mus musculus	65-69
16251411-8	2005	Thus, SP-C functions to limit lung inflammation, inhibit collagen accumulation, and restore normal lung structure after bleomycin.	Bleomycin	120-129	sparse coat	Mus musculus	6-10
15169678-8	2004	SP-B and SP-C, but not SP-A, localized predominantly to the glycogen stores.	Glycogen	60-68	sparse coat	Mus musculus	9-13
14565945-3	2004	Secretion of phosphatidylcholine, surfactant protein (SP)-B and SP-C was stimulated by terbutaline, 5"-N-ethylcarboxyamidoadenosine (NECA), ATP, UTP, TPA, and ionomycin.	Terbutaline	87-98	sparse coat	Mus musculus	64-68
14565945-3	2004	Secretion of phosphatidylcholine, surfactant protein (SP)-B and SP-C was stimulated by terbutaline, 5"-N-ethylcarboxyamidoadenosine (NECA), ATP, UTP, TPA, and ionomycin.	5"-n-ethylcarboxyamidoadenosine	100-131	sparse coat	Mus musculus	64-68
14565945-3	2004	Secretion of phosphatidylcholine, surfactant protein (SP)-B and SP-C was stimulated by terbutaline, 5"-N-ethylcarboxyamidoadenosine (NECA), ATP, UTP, TPA, and ionomycin.	Adenosine-5'-(N-ethylcarboxamide)	133-137	sparse coat	Mus musculus	64-68
14565945-3	2004	Secretion of phosphatidylcholine, surfactant protein (SP)-B and SP-C was stimulated by terbutaline, 5"-N-ethylcarboxyamidoadenosine (NECA), ATP, UTP, TPA, and ionomycin.	Adenosine Triphosphate	140-143	sparse coat	Mus musculus	64-68
14565945-3	2004	Secretion of phosphatidylcholine, surfactant protein (SP)-B and SP-C was stimulated by terbutaline, 5"-N-ethylcarboxyamidoadenosine (NECA), ATP, UTP, TPA, and ionomycin.	Uridine Triphosphate	145-148	sparse coat	Mus musculus	64-68
14565945-3	2004	Secretion of phosphatidylcholine, surfactant protein (SP)-B and SP-C was stimulated by terbutaline, 5"-N-ethylcarboxyamidoadenosine (NECA), ATP, UTP, TPA, and ionomycin.	Tetradecanoylphorbol Acetate	150-153	sparse coat	Mus musculus	64-68
14565945-3	2004	Secretion of phosphatidylcholine, surfactant protein (SP)-B and SP-C was stimulated by terbutaline, 5"-N-ethylcarboxyamidoadenosine (NECA), ATP, UTP, TPA, and ionomycin.	Ionomycin	159-168	sparse coat	Mus musculus	64-68
12598228-9	2003	Finally, SpC-GM mice were protected from fluorescein isothiocyanate-induced pulmonary fibrosis.	Fluorescein-5-isothiocyanate	41-67	sparse coat	Mus musculus	9-12
12114186-6	2002	Secretion of SP-B, SP-C, and phosphatidylcholine was stimulated by phorbol 12-myristate 13-acetate and was inhibited by compound 48/80.	Tetradecanoylphorbol Acetate	67-98	sparse coat	Mus musculus	19-23
11839528-7	2002	Immunocytochemistry showed that with T(3) treatment, Nkx2.1 and surfactant protein SP-C proteins became progressively localized to cuboidal epithelial cells and mesenchymal expression of Hoxb5 was reduced, a pattern resembling late fetal lung development.	Triiodothyronine	37-41	sparse coat	Mus musculus	83-87
9252553-2	1997	Binding and uptake of SP-C were detected using fluorescently labeled SP-C and dinitrophenyl-labeled SP-C (DNP-SP-C).	dinitrophenyl	78-91	sparse coat	Mus musculus	22-26
11557581-5	2001	We found that among the different hydrophobic components of mouse surfactant separated by gel filtration or reverse-phase HPLC, only SP-C exhibited the capacity to bind to a tritium-labeled LPS.	Tritium	174-181	sparse coat	Mus musculus	133-137
11159019-3	2001	Association of [(3)H]DPPC with alveolar macrophages from GM(-/-), wild-type, and SP-C-GM mice was similar; however, catabolism of DPPC was markedly reduced in cells from GM(-/-) mice.	[(3)h]dppc	15-25	sparse coat	Mus musculus	81-85
11159019-3	2001	Association of [(3)H]DPPC with alveolar macrophages from GM(-/-), wild-type, and SP-C-GM mice was similar; however, catabolism of DPPC was markedly reduced in cells from GM(-/-) mice.	gm	86-88	sparse coat	Mus musculus	81-85
10710533-7	2000	The reductions in phospholipid, SP-B, and SP-C in LA fractions measured during PCP were associated with an increase in the minimum surface tension of LAs as measured by pulsating bubble surfactometer (13.1 +/- 1.1 vs. 5.4 +/- 1.8 mN/m; P < 0.05).	Lanthanum	150-153	sparse coat	Mus musculus	42-46
9458794-2	1998	Using a mouse lung epithelial cell line, we are exploring RA-Dex interactions through the study of RA and Dex effects on RA receptor (RAR) and surfactant protein (SP) C mRNA expression.	Dexamethasone	106-109	sparse coat	Mus musculus	143-168
9458794-5	1998	Dex decreased RAR-beta and SP-C expression to 75 and 70% of control values, respectively, with greatest effects at 48 h and at 10(-7) M. There was no effect of Dex on either RAR-beta or SP-C mRNA disappearance with actinomycin D.	Dexamethasone	0-3	sparse coat	Mus musculus	27-31
9458794-7	1998	Despite Dex, RA increased both RAR-beta and SP-C mRNA.	Tretinoin	13-15	sparse coat	Mus musculus	44-48
11874100-6	2002	In SP-C-rtTA mice, exposure of the pregnant dam to doxycycline induced luciferase activity in fetal lung tissue as early as E10.5.	Doxycycline	51-62	sparse coat	Mus musculus	3-7
11874100-9	2002	In the SP-C-rtTA mice, luciferase activity was detected in the absence of doxycycline but was enhanced approximately 10-fold by administration of drugs.	Doxycycline	74-85	sparse coat	Mus musculus	7-11
11238011-1	2001	Transgenic mice in which fibroblast growth factor (FGF)-10 was expressed in the lungs of fetal and postnatal mice were generated with a doxycycline-inducible system controlled by surfactant protein (SP) C or Clara cell secretory protein (CCSP) promoter elements.	Doxycycline	136-147	sparse coat	Mus musculus	179-204
9458815-0	1998	Nicotine stimulates branching and expression of SP-A and SP-C mRNAs in embryonic mouse lung culture.	Nicotine	0-8	sparse coat	Mus musculus	57-61
9357844-2	1997	Overexpression of GM-CSF only in respiratory epithelial cells of mice deficient in GM-CSF using the SP-C promotor (GM-/-,SP-C-GM+/+) resulted in increased type II cell numbers and normalization of alveolar Sat PC pool sizes.	gm-/-	115-120	sparse coat	Mus musculus	100-104
9357844-2	1997	Overexpression of GM-CSF only in respiratory epithelial cells of mice deficient in GM-CSF using the SP-C promotor (GM-/-,SP-C-GM+/+) resulted in increased type II cell numbers and normalization of alveolar Sat PC pool sizes.	gm	18-20	sparse coat	Mus musculus	100-104
9357844-2	1997	Overexpression of GM-CSF only in respiratory epithelial cells of mice deficient in GM-CSF using the SP-C promotor (GM-/-,SP-C-GM+/+) resulted in increased type II cell numbers and normalization of alveolar Sat PC pool sizes.	gm	18-20	sparse coat	Mus musculus	121-125
9357844-4	1997	The clearance of dipalmitoylphosphatidylcholine and SP-B from the airspaces was more rapid for GM-/-,SP-C-GM+/+ mice than for GM+/+ mice.	1,2-Dipalmitoylphosphatidylcholine	17-47	sparse coat	Mus musculus	101-105
9357844-4	1997	The clearance of dipalmitoylphosphatidylcholine and SP-B from the airspaces was more rapid for GM-/-,SP-C-GM+/+ mice than for GM+/+ mice.	gm	95-97	sparse coat	Mus musculus	101-105
9357844-4	1997	The clearance of dipalmitoylphosphatidylcholine and SP-B from the airspaces was more rapid for GM-/-,SP-C-GM+/+ mice than for GM+/+ mice.	gm	106-108	sparse coat	Mus musculus	101-105
9357845-2	1997	Lung weight and volume were significantly increased in SP-C-GM mice compared with GM+/+ or GM-/- control mice.	gm	60-62	sparse coat	Mus musculus	55-59
9357845-4	1997	Abundance of type II cells per mouse lung was increased three- to fourfold in SP-C-GM mice compared with GM+/+ and GM-/- mice.	gm	83-85	sparse coat	Mus musculus	78-82
9252553-2	1997	Binding and uptake of SP-C were detected using fluorescently labeled SP-C and dinitrophenyl-labeled SP-C (DNP-SP-C).	2,4-Dinitrophenol	106-109	sparse coat	Mus musculus	22-26
8514651-1	1993	Hamycin incorporated into liposomes containing phosphatidylcholine (SPC) and phosphatidic acid (PA) had reduced toxicity and an enhanced antifungal activity in experimental aspergillosis in balb/c mice.	hamycin	0-7	sparse coat	Mus musculus	68-71
9092492-9	1997	Collectively, these results demonstrate a role for the C-terminal propeptide of SP-B in SP-C proprotein processing and the maintenance of lamellar body size.	propeptide	66-76	sparse coat	Mus musculus	88-92
8601721-1	1996	Spingosylphosphorylcholine (lysosphingomyelin or SPC) is an effective and broad spectrum cell growth promoting agent and a candidate for evaluation on wound healing.	spingosylphosphorylcholine	0-26	sparse coat	Mus musculus	49-52
8601721-1	1996	Spingosylphosphorylcholine (lysosphingomyelin or SPC) is an effective and broad spectrum cell growth promoting agent and a candidate for evaluation on wound healing.	sphingosine phosphorylcholine	28-45	sparse coat	Mus musculus	49-52
8514651-1	1993	Hamycin incorporated into liposomes containing phosphatidylcholine (SPC) and phosphatidic acid (PA) had reduced toxicity and an enhanced antifungal activity in experimental aspergillosis in balb/c mice.	Phosphatidylcholines	47-66	sparse coat	Mus musculus	68-71
8514651-3	1993	The LD50 (mg/kg) of hamycin contained in SPC/cholesterol/PA (molar ratio 4:5:1) liposomes was 2.8 whereas that in SPC/PA liposomes (molar ratio 9:1) was 0.35.	hamycin	20-27	sparse coat	Mus musculus	41-44
8514651-5	1993	On the other hand the presence of cholesterol in the carrier phosphatidic acid liposomes (SPC/cholesterol/PA; molar ratio 4:5:1) at a similar dose (0.1 mg/kg) led to a 60% survival over the same time period.	Cholesterol	34-45	sparse coat	Mus musculus	90-93
8514651-5	1993	On the other hand the presence of cholesterol in the carrier phosphatidic acid liposomes (SPC/cholesterol/PA; molar ratio 4:5:1) at a similar dose (0.1 mg/kg) led to a 60% survival over the same time period.	Phosphatidic Acids	61-78	sparse coat	Mus musculus	90-93